Buffington Mohr McNeal Acquires 5,200 Shares of Pfizer Inc. (NYSE:PFE)

Buffington Mohr McNeal increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 41.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,650 shares of the biopharmaceutical company’s stock after purchasing an additional 5,200 shares during the quarter. Buffington Mohr McNeal’s holdings in Pfizer were worth $508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Worth Asset Management LLC bought a new position in shares of Pfizer during the first quarter valued at $29,000. Briaud Financial Planning Inc bought a new position in Pfizer in the third quarter valued at about $30,000. Sanctuary Wealth Management L.L.C. bought a new position in Pfizer in the fourth quarter valued at about $50,000. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.11 during midday trading on Tuesday, reaching $25.80. 13,327,945 shares of the company were exchanged, compared to its average volume of 42,333,582. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average is $27.27 and its two-hundred day moving average is $28.84. Pfizer Inc. has a one year low of $25.61 and a one year high of $41.33. The stock has a market cap of $146.09 billion, a PE ratio of 71.69, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.